Beijing Progen Biotechnology Development Co., Ltd.

Home
About
Scientific research technology
Products
Project
Blog
Career
Contact

Quantitative Detection Kit for Heat Shock Protein 90α (ELISA)

Hsp90α is an intracellular chaperone protein that assists in protein folding and maintains the stability of various intracellular signaling proteins, thereby promoting cell survival and growth. However, in tumor cells, Hsp90α can maintain the activity of overactivated or mutated signaling proteins, accelerating the malignant transformation of tumor cells. In recent years, it has been found that Hsp90α can be secreted by tumor cells into the extracellular space and plays an important role in the distal invasion and metastasis of tumor cells.

Keywords

Propylene glycol quaternary ammonium salt disinfectant

Related Products

Get a Quote

Product Details

[Product Name] Quantitative Detection Kit for Heat Shock Protein 90α (ELISA)

[Packaging Specifications] 48 tests/box; 96 tests/box

[Product Introduction]

Heat shock protein 90α (Hsp90α) is a novel tumor marker and an important member of the heat shock protein family. The Luo Yongzhang team at the "National Engineering Research Center for Protein Technology" was the first in the world to report the regulatory mechanism of tumor cell-specific secretion of Hsp90α. They also revealed the molecular differences between secreted and intracellular Hsp90α, and further demonstrated that secreted Hsp90α can promote tumor invasion and metastasis, and its blood concentration is positively correlated with the malignancy of the tumor.

Clinical trial results using hepatocellular carcinoma and lung cancer as indications found that the concentration of Hsp90α in the plasma of cancer patients was significantly higher than that in healthy people and those with benign lesions (including benign tumors). The sensitivity for diagnosing hepatocellular carcinoma was 93%, twice that of AFP; the sensitivity for diagnosing lung cancer was 70%, and the combined sensitivity with CEA was 85%, and with CYFRA21-1 was 87%. Dynamic monitoring results from surgical procedures showed a significant statistical difference between pre- and post-operative levels; dynamic monitoring results from medical treatment showed that the change trend of Hsp90α levels before and after treatment corresponded to the changes in the patient's condition.

The Hsp90α quantitative detection kit obtained the National Class III Medical Device Registration Certificate issued by the State Food and Drug Administration in April 2013, and passed the ISO 13485 system and EU CE certification in the same year. This is the world's first clinical product using human Hsp90α since its discovery. On November 17 of the same year, Tsinghua University held a release conference for the Hsp90α achievement, which generated a wide and strong social response: that evening, CCTV News broadcast a 1-minute and 49-second focused report, and more than 170 major domestic media outlets, including Xinhua News Agency, carried long feature reports on the front page. Dr. James Watson, discoverer of the DNA double helix structure and Nobel laureate, sent a congratulatory letter, praising this achievement as "a big step forward in the fight against cancer"; it was included by the Ministry of Science and Technology in the "Twelfth Five-Year Plan" major original achievements; and General Secretary Xi Jinping included it among ten fundamental scientific breakthroughs since the founding of the People's Republic of China in his speech at the May 30, 2016 Science and Technology Conference.

[Product Use] Suitable for auxiliary diagnosis of tumors, disease monitoring and efficacy evaluation, prognosis assessment, etc.

[Product Advantages]

Earlier: Helps in early tumor detection

More Comprehensive: Tracks the entire process of tumor genesis and development

More Accurate: Highly consistent with clinical results

Safe and Non-invasive: 2ml peripheral blood

[Clinical Value]

Risk assessment and early detection in high-risk individuals for tumors

Auxiliary diagnosis and staging of tumors

Monitoring of disease and efficacy evaluation, prognosis assessment in tumor treatment

Follow-up and recurrence monitoring of tumors

None